Early NSCLC: New Topographies in Non–Small Cell Lung Cancer Research

Sandip P. Patel, MD


August 11, 2022

Sandip P. Patel, MD, speculates on promising research directions in early non–small cell lung cancer (NSCLC), including enlarged exploration of driver mutations and their implications for the standard treatment options, the dilemmas surrounding patients who do not achieve complete pathologic response after neoadjuvant therapy, and the earlier use of targeted and immunotherapies in the effort to improve survival rates.

Together, Dr Patel suggests, these lines of investigation form a map that represents the quickly evolving topography in the area of NSCLC therapeutics.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.